X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
benzodiazepinones - pharmacology (2458) 2458
animals (2411) 2411
male (1861) 1861
rats (1456) 1456
humans (1025) 1025
female (603) 603
pharmacology & pharmacy (602) 602
mice (579) 579
devazepide (574) 574
benzodiazepines (518) 518
rats, inbred strains (476) 476
dose-response relationship, drug (453) 453
receptors, cholecystokinin - antagonists & inhibitors (450) 450
benzodiazepinones - metabolism (443) 443
flumazenil (381) 381
adult (372) 372
in vitro techniques (357) 357
cholecystokinin - antagonists & inhibitors (342) 342
kinetics (314) 314
diazepam - pharmacology (307) 307
cholecystokinin (289) 289
receptors, gaba-a - drug effects (286) 286
time factors (272) 272
pirenzepine (270) 270
neurosciences (268) 268
phenylurea compounds (267) 267
rats, sprague-dawley (257) 257
receptors, gaba-a - metabolism (252) 252
anti-anxiety agents - pharmacology (242) 242
index medicus (242) 242
benzodiazepines - pharmacology (232) 232
benzodiazepinones - therapeutic use (222) 222
brain - metabolism (204) 204
sincalide - pharmacology (204) 204
benzodiazepinones - administration & dosage (199) 199
anti-anxiety agents (192) 192
rat (192) 192
rats, wistar (186) 186
biochemistry & molecular biology (183) 183
middle aged (181) 181
drug interactions (177) 177
brain (168) 168
cholecystokinin - pharmacology (168) 168
ligands (168) 168
isoquinolines - pharmacology (165) 165
clonazepam - pharmacology (163) 163
guinea pigs (161) 161
phenylurea compounds - pharmacology (155) 155
dogs (151) 151
potent (150) 150
benzodiazepinones - chemistry (144) 144
convulsants - pharmacology (144) 144
receptors, cholecystokinin - drug effects (143) 143
diazepam (142) 142
receptors, cholecystokinin - physiology (142) 142
structure-activity relationship (142) 142
benzodiazepinones - chemical synthesis (141) 141
physiology (140) 140
receptors (139) 139
hormone antagonists - pharmacology (138) 138
cck (137) 137
carbolines - pharmacology (133) 133
brain - drug effects (132) 132
pancreas - drug effects (132) 132
behavior, animal - drug effects (131) 131
binding, competitive (131) 131
indoles - pharmacology (131) 131
atropine - pharmacology (128) 128
binding sites (125) 125
chemistry, medicinal (125) 125
receptors, cholecystokinin - metabolism (123) 123
benzodiazepinones - blood (121) 121
motor activity - drug effects (121) 121
l-365,260 (120) 120
cholecystokinin - physiology (118) 118
cells, cultured (114) 114
gastrin (110) 110
receptors, gaba-a (110) 110
aged (107) 107
cerebral cortex - metabolism (106) 106
anticonvulsants - pharmacology (104) 104
benzodiazepine (104) 104
muscle contraction - drug effects (103) 103
antagonist (101) 101
expression (101) 101
receptor, cholecystokinin b (100) 100
benzodiazepines - antagonists & inhibitors (94) 94
binding (94) 94
pancreas - metabolism (94) 94
ro 15-1788 (94) 94
research article (92) 92
double-blind method (91) 91
pyrazoles - pharmacology (91) 91
receptors, gaba-a - physiology (88) 88
benzodiazepinones - adverse effects (87) 87
receptors, muscarinic - drug effects (87) 87
cells (86) 86
drug synergism (86) 86
electroencephalography (86) 86
endocrinology & metabolism (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2997) 2997
Russian (110) 110
Japanese (83) 83
German (41) 41
French (26) 26
Chinese (13) 13
Italian (9) 9
Spanish (4) 4
Portuguese (2) 2
Czech (1) 1
Hungarian (1) 1
Polish (1) 1
Romanian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Cancer, ISSN 1471-2407, 08/2014, Volume 14, Issue 1, pp. 570 - 570
Journal Article
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 04/2008, Volume 93, Issue 4, pp. 533 - 542
Activating NOTCH1 mutations are common in T-cell acute lymphoblastic leukemia. Inhibition of NOTCH1 signaling with gamma-secretase inhibitors causes cell cycle... 
Inhibitor | NOTCH1 | T-cell | γ-secretase | Oncogene | Piperazines - administration & dosage | Vincristine - pharmacology | Apoptosis - drug effects | Humans | Daunorubicin - pharmacology | Neoplasm Proteins - antagonists & inhibitors | Carbamates - administration & dosage | Cell Line, Tumor - drug effects | Antineoplastic Agents - administration & dosage | Enzyme Inhibitors - administration & dosage | Dexamethasone - pharmacology | Leukemia-Lymphoma, Adult T-Cell - drug therapy | Vincristine - administration & dosage | Antineoplastic Agents - pharmacology | Neoplasm Proteins - genetics | Daunorubicin - administration & dosage | Carbamates - pharmacology | Dexamethasone - administration & dosage | Cell Line, Tumor - enzymology | Leukemia-Lymphoma, Adult T-Cell - genetics | Pyrimidines - administration & dosage | Benzodiazepinones - pharmacology | Dipeptides - pharmacology | Enzyme Inhibitors - pharmacology | Leukemia-Lymphoma, Adult T-Cell - pathology | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Sequence Analysis, DNA | Cell Division - drug effects | Drug Synergism | Dipeptides - administration & dosage | Oncogene Proteins, Fusion - genetics | Oncogene Proteins, Fusion - antagonists & inhibitors | Amyloid Precursor Protein Secretases - antagonists & inhibitors | Benzamides | DNA, Neoplasm - genetics | Mutation | Receptor, Notch1 - antagonists & inhibitors | Cell Cycle - drug effects | In Vitro Techniques | Receptor, Notch1 - genetics | Drug Screening Assays, Antitumor | FUSION | gamma-secretase | C-MYC | oncogene | REARRANGEMENT | inhibitor | PATHWAY | ACTIVATING NOTCH1 MUTATIONS | RESISTANCE | ABL1 | HEMATOLOGY | Index Medicus
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 09/2015, Volume 97, Issue 1, pp. 51 - 61
[Display omitted] Microtubules are critical elements that are involved in a wide range of cellular processes, and thus, they have become an attractive target... 
G2/M phase arrest | Microtubule | Anti-proliferative activity | Apoptosis | Xenograft tumours | Cisplatinum (PubChem CID: 441203) | Vincristine (PubChem CID: 5978) | Chemical compounds studied in this article Combretastatin A-4 (PubChem CID:5351344) | Colchicine (PubChem CID: 6167) | Taxol (PubChem CID: 36314) | G/M phase arrest | ANGIOGENESIS | MECHANISMS | DEATH | MICROTUBULE-INTERFERING AGENTS | TUMOR VASCULATURE | PATHWAY | TARGETS | PHARMACOLOGY & PHARMACY | CANCER STATISTICS | ANTICANCER DRUGS | Lung Neoplasms - drug therapy | Organophosphates - adverse effects | Drugs, Investigational - adverse effects | Drugs, Investigational - pharmacology | Human Umbilical Vein Endothelial Cells - metabolism | Apoptosis - drug effects | Tubulin Modulators - pharmacology | Humans | Lung Neoplasms - metabolism | Organophosphates - therapeutic use | Drugs, Investigational - therapeutic use | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Stilbenes - chemistry | Drugs, Investigational - chemistry | Microtubules - metabolism | Tubulin - metabolism | Antineoplastic Agents - adverse effects | Microtubules - drug effects | Human Umbilical Vein Endothelial Cells - cytology | Antineoplastic Agents - pharmacology | Tubulin - chemistry | Tubulin Modulators - adverse effects | Tubulin Modulators - chemistry | Human Umbilical Vein Endothelial Cells - drug effects | Benzodiazepinones - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Cells, Cultured | Random Allocation | Antineoplastic Agents - chemistry | Benzodiazepinones - chemistry | Tubulin Modulators - therapeutic use | Organophosphates - pharmacology | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Cell Line, Tumor | Organophosphates - chemistry | Cell Proliferation - drug effects | Mice, Inbred BALB C | Molecular Docking Simulation | Carcinoma, Non-Small-Cell Lung - drug therapy | Benzodiazepinones - therapeutic use | Benzodiazepinones - adverse effects | Tubulins | Tumors
Journal Article
Cancer Letters, ISSN 0304-3835, 08/2018, Volume 428, pp. 104 - 116
The acquisition of resistance is a major obstacle to the clinical use of platinum drugs for ovarian cancer treatment. Increase of DNA damage response is one of... 
High throughput screen | Cisplatin resistance | DUOXA1 | ATR-Chk1 | ROS | Ovarian cancer | SURVIVAL | CELLS | OXIDATIVE STRESS | DNA-DAMAGE | CHEMOTHERAPY | ONCOLOGY | PLATINUM RESISTANCE | CHECKPOINT | INHIBITOR | DUAL OXIDASE | MOLECULAR-MECHANISMS | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Reactive Oxygen Species - metabolism | Ataxia Telangiectasia Mutated Proteins - metabolism | Humans | Middle Aged | Ovarian Neoplasms - pathology | Ovarian Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Urea - analogs & derivatives | Female | Membrane Proteins - metabolism | Ovarian Neoplasms - drug therapy | Pyrazoles - pharmacology | Benzodiazepinones - pharmacology | Checkpoint Kinase 1 - antagonists & inhibitors | Kaplan-Meier Estimate | Thiophenes - pharmacology | Cisplatin - pharmacology | Xenograft Model Antitumor Assays | Checkpoint Kinase 1 - metabolism | Urea - therapeutic use | Animals | Cisplatin - therapeutic use | Membrane Proteins - antagonists & inhibitors | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Cell Line, Tumor | Aged | Mice | Benzodiazepinones - therapeutic use | Urea - pharmacology | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Oxidases | Medical research | RNA | Medicine, Experimental | Antineoplastic agents
Journal Article
Journal Article
by Wen, D and Sun, D and Zang, G and Hao, L and Liu, X and Yu, F and Ma, C and Cong, B
Neuroscience, ISSN 0306-4522, 2014, Volume 277, pp. 14 - 25
Journal Article